tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Arthritis, Experimental D001169 24 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Ascites D001201 25 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Brain Diseases D001927 27 associated lipids
Endotoxemia D019446 27 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Kidney Diseases D007674 29 associated lipids
Obesity D009765 29 associated lipids
Catalepsy D002375 30 associated lipids
Dermatitis D003872 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Proteinuria D011507 30 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Antonini TM et al. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation. 2015 AIDS pmid:25387314
Nowak P et al. Follow-up of antiretroviral treatment in liver transplant recipients with primary and chronic HIV type 1 infection. 2003 AIDS Res. Hum. Retroviruses pmid:12581512
Sklar EM Post-transplant neurotoxicity: what role do calcineurin inhibitors actually play? 2006 AJNR Am J Neuroradiol pmid:16971594
Bargalló N et al. Cortical laminar necrosis caused by immunosuppressive therapy and chemotherapy. 2000 AJNR Am J Neuroradiol pmid:10730638
Bartynski WS et al. Etiology of cortical and white matter lesions in cyclosporin-A and FK-506 neurotoxicity. 2001 Nov-Dec AJNR Am J Neuroradiol pmid:11733324
Bartynski WS et al. Pretransplantation conditioning influence on the occurrence of cyclosporine or FK-506 neurotoxicity in allogeneic bone marrow transplantation. 2004 AJNR Am J Neuroradiol pmid:14970028
Bartynski WS et al. Posterior reversible encephalopathy syndrome after solid organ transplantation. 2008 AJNR Am J Neuroradiol pmid:18272559
Schuuring J et al. Severe tacrolimus leukoencephalopathy after liver transplantation. 2003 Nov-Dec AJNR Am J Neuroradiol pmid:14625238
Oliverio PJ et al. Reversible tacrolimus-induced neurotoxicity isolated to the brain stem. 2000 AJNR Am J Neuroradiol pmid:10954277
Appignani BA et al. Neuroimaging findings in patients on immunosuppressive therapy: experience with tacrolimus toxicity. 1996 AJR Am J Roentgenol pmid:8623651
Srinivas NR Letter: sublingual dosing of tacrolimus in transplant patients-interesting concept to overcome first pass effects. 2017 Aliment. Pharmacol. Ther. pmid:28589592
Ierardi E et al. Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. 2001 Aliment. Pharmacol. Ther. pmid:11207512
Romano C et al. Oral tacrolimus (FK 506) in refractory paediatric ulcerative colitis. 2010 Aliment. Pharmacol. Ther. pmid:20148798
Beckebaum S et al. Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients. 2009 Aliment. Pharmacol. Ther. pmid:19624550
Firpi RJ et al. Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent. 2004 Aliment. Pharmacol. Ther. pmid:15113371
Solari S et al. Sublingual tacrolimus administration provides similar drug exposure to per-oral route employing lower doses in liver transplantation: a pilot study. 2017 Aliment. Pharmacol. Ther. pmid:28261844
Hisanaga Y et al. Implication of nitric oxide synthase activity in the genesis of water immersion stress-induced gastric lesions in rats: the protective effects of FK506. 1996 Aliment. Pharmacol. Ther. pmid:8971291
Hoshino H et al. Effects of FK506 on an experimental model of colitis in rats. 1995 Aliment. Pharmacol. Ther. pmid:7544633
Yamamoto T et al. Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis--authors' reply. 2016 Aliment. Pharmacol. Ther. pmid:27040167
Taylor KM and Sparrow MP Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis. 2016 Aliment. Pharmacol. Ther. pmid:27040166